IA-Group is a strategic partner to bio-pharmacutical companies. We bring extensive therapeutic knowledge and regulatory expertise in strategic use of clinical imaging to enhance understanding of the mode of action, to increase the efficiency of clinical decisions and to accelerate drug development.
IA’s operations team leverage our global footprint and the next-generation cloud based proprietry platform Dynamika to de-risk trial execution and to ensure data quality and integrity. Our venture arm pioneer unique targeted investment and risk-sharing models to enable our clients to reach the next value inflection point faster. We fuse decades of theraputic insight and agile culture to meet today's speed and high standard of therapeutic innovation.
Diana RoettgerHead of Scientific and Medical Affairs
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst™-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA laboratory in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.
Thomas SchlumpbergerVP Business Development
Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system. ntract Pharma is a licensing and product development company offering state-of-the-art formulation technologies and specialist gastrointestinal models to develop advanced new therapeutics
Invest Liverpool is the Mayor of Liverpool’s economic investment agency. Invest Liverpool offers a range of services to support companies looking to collaborate, expand or invest in Liverpool City Region. Health & Life Sciences is a priority sector and we welcome conversations about investing in the industry.
We are investing billions of pounds in our health ecosystem, offering countless opportunities from research, drug discovery, and clinical trials through to bio-manufacturing.
Investment in health and life sciences is driving innovation in specialist areas such as: Infection, Precision Medicine, Children’s Health, Veterinary Science, Healthy and Independent Living, Big Data, Sensors and Internet of Things.
With hundreds of medical companies based here, the area is part of the Liverpool-Manchester life sciences corridor, one of the UK’s top three clusters of biomedical activity.
Health and Life Sciences companies that share our passion for research and discovery will be impressed by the quality and quantity of world-class R&D that is conducted here. Our schools, colleges and universities are working alongside big pharma and start-ups to build an exceptional talent pool.
Invest Liverpool welcomes conversations with companies about investing in health and life sciences.